FDA Announces Approval of Esketamine Nasal Spray For Treatment of Drug Resistant Major Depressive Disorder

In an overwhelming approval the FDA approved the use of Esketamine nasal spary, known as <em>SPRAVATO™, </em>for the treatment of drug resistant major depressive disorder. A major step for those that support the use of ketamine in the treatment of depression.